Shereen Rafee

St. James's Hospital, D08 NHY1 Dublin
Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545.

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545.

Journal: International journal of molecular sciences

Published: March 23, 2026

RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).

RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).

Journal: International journal of molecular sciences

Published: May 03, 2023

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer.

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer.

Journal: Oncology and therapy

Published: January 05, 2022

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.

Journal: Journal of translational medicine

Published: February 10, 2021

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.

Journal: Journal of translational medicine

Published: September 06, 2019

Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?

Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 04, 2019

Body Fatness and Cancer.

Body Fatness and Cancer.

Journal: The New England journal of medicine

Published: December 14, 2016

Targeting the fibroblast growth factor receptor family in cancer.

Targeting the fibroblast growth factor receptor family in cancer.

Journal: Cancer treatment reviews

Published: November 13, 2015

Thymidine Phosphorylase in Cancer; Enemy or Friend?

Thymidine Phosphorylase in Cancer; Enemy or Friend?

Journal: Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Published: March 19, 2015

Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.

Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.

Journal: Tumori

Published: October 14, 2014

A rare case of nasopharyngeal carcinoma with widespread CNS metastases.

A rare case of nasopharyngeal carcinoma with widespread CNS metastases.

Journal: Irish medical journal

Published: July 04, 2014

Immune effects of bevacizumab: killing two birds with one stone.

Immune effects of bevacizumab: killing two birds with one stone.

Journal: Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Published: March 17, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026